Triptorelin Market Insights With Key Players psen, Bachem, Ferring Pharmaceuticals, Chengdu Tiantaishan pharmaceutical, Tecnofarma

The global triptorelin market size was valued at US$ 426.4 Mn in 2017, and is expected to witness a CAGR of 5.2% over the forecast period (2018 – 2026).

Gonadotropin-releasing hormone (GnRH) agonists have greater safety and efficacy profile than estrogens and anti-androgens among various therapies of achieving medical castration. Furthermore, slow-release formulations of GnRH agonists offer patients flexibility, improves quality of life, and eventually reduce cost.

Most of the times, prostate cancer progresses with increasing testosterone hormone. Moreover, the production of testosterone can be stopped by surgically removing the testicles or thorough medication therapy. Triptorelin is GnRH agonists which is designed to stop the tentacles from making testosterone. This eventually reduces testosterone levels and minimizes progression of prostate cancer.

Triptorelin is a decapeptide analogue of Luteinising Hormone-Releasing Hormone (LHRH, also called gonadotropin-releasing hormone [GnRH]). Triptorelin is extensively used in palliative treatment of hormone dependent advanced prostate cancer.

Moreover, according to National Institute for Health and Care Excellence (NICE), in May 2013, the licensed indications for luteinising hormone-releasing hormone (LHRH) agonist: triptorelin were extended to include two new indications for prostate cancer: first in neoadjuvant treatment before radiotherapy in high-risk localized or locally advanced disease and second in adjuvant treatment to radical prostatectomy in locally advanced disease at high risk of progression. Triptorelin is administrated intramuscularly or subcutaneously.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1963

Furthermore, triptorelin is indicated for the treatment of pediatric patients two years of age and older with Central Precocious Puberty (CPP). In July 2017, U.S. Food and Drug Administration (FDA), approved Arbor Pharmaceuticals’: Triptodur, in pediatric patients with central precocious puberty. The approval follows a phase 3 clinical trial (Efficacy, Safety, and Pharmacokinetics [PK] of Triptorelin 6-month Formulation in Patients with Central Precocious Puberty), which examines prepubertal luteinizing hormone levels using triporelin therapy. Study demonstrated a return to pre-pubertal luteinizing hormone (LH) levels in 93% of enrolled patients, with pre-pubertal luteinizing hormone (LH) suppression maintained at 12 months by 98% of patients.

The GnRH agonist, triptorelin is a first-line hormonal therapy, which offers efficacy and safety in clinical trials of patients with non-metastatic or metastatic prostate cancer. Furthermore, triptorelin has been increasingly studied for varied treatment options, present in clinical development phases. For instance, GnRH analogue, triptorelin is being studied to analyze their efficacy and safety for HIV-1 reservoir reduction in Antiretroviral Therapy (ART) treated HIV-1 infected patients. According to ClinicalTrials.gov, in May 2018, this study was conducted by Immune System Regulation AB, and currently in phase II clinical stage.

Triptorelin is further being studied to analyze effects of adjuvant hormonal therapy treatments of Tamoxifen, Letrozole and Letrozole + Zoledronate on bone loss in breast cancer patients. According to ClinicalTrials.gov, in July 2017, this study was sponsored by National Cancer Institute (NCI), Naples; and currently present in phase III clinical stage. Moreover, triptorelin market shows lucrative revenue growth in the near future, with the successful completion of this study and potential launch of new products during the forecast period.

Moreover, higher efficacy and effectiveness of triptorelin in the suppression of gonadotropin in Central Precocious Puberty (CPP) among young boys and girls is expected to drive the triptorelin market growth. For instance, according to data published in the Scientific World Journal, in May 2012, triptorelin 11.25 mg per 90 days efficiently suppressed the pituitary-gonadal level in children with CPP from first administration.

Furthermore, increasing research and development activities focused on application of androgen deprivation therapy with triptorelin to lower progression of salivary gland cancer expressing androgen receptors. For instance, in January 2016, Debiopharm International SA collaborated with European Organization for Research and Treatment of Cancer (EORTC) to investigate Triptorelin for treatment of salivary gland cancer. Under the collaboration, Debiopharm International SA will supply triptorelin pamoate 3.75 mg 1-month formulation to patients suffering from salivary gland cancer participating in a clinical study sponsored by EORTC. During the clinical study, researchers will evaluate the efficacy and safety of androgen chemotherapy versusandrogen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptors-expressing salivary gland cancers.

Get Discount On This Report:
https://www.coherentmarketinsights.com/insight/request-discount/1963

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.